Navidea Biopharmaceuticals has announced the completion of a clinical trial of its NAV4694 radiopharmaceutical, a biomarker used to identify cerebral beta amyloid in potential Alzheimer's disease cases. Results of the study, which was intended to determine the safety and efficacy of the biomarker when used with PET imaging, will be presented at this year's SNMMI Annual Meeting. Researchers are planning for a Phase III study of the agent this year. Meanwhile, Navidea said it has also secured rights to two other beta amyloid PET imaging agents from AstraZeneca: AZD2184 and AZD2995.

Related Summaries